WallStSmart

BeiGene, Ltd. (ONC)vsRAPT Therapeutics Inc (RAPT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).

ONC

Hold

42

out of 100

Grade: D

Growth: 8.0Profit: 5.0Value: 3.0Quality: 6.5
Piotroski: 5/9Altman Z: 0.26

RAPT

Avoid

21

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -2.26
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ONCSignificantly Overvalued (-1999.6%)

Margin of Safety

-1999.6%

Fair Value

$16.73

Current Price

$282.72

$265.99 premium

UndervaluedFair: $16.73Overvalued

Intrinsic value data unavailable for RAPT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ONC2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
32.8%10/10

Revenue surging 32.8% year-over-year

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

RAPT1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Areas to Watch

ONC4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
7.5%3/10

ROE of 7.5% — below average capital efficiency

Profit MarginProfitability
5.4%3/10

5.4% margin — thin

P/E RatioValuation
114.8x2/10

Premium valuation, high expectations priced in

RAPT4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.68B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : ONC

The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.

Bull Case : RAPT

The strongest argument for RAPT centers on Debt/Equity.

Bear Case : ONC

The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 114.8x leaves little room for execution misses.

Bear Case : RAPT

The primary concerns for RAPT are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

ONC profiles as a hypergrowth stock while RAPT is a value play — different risk/reward profiles.

ONC carries more volatility with a beta of 0.52 — expect wider price swings.

ONC is growing revenue faster at 32.8% — sustainability is the question.

ONC generates stronger free cash flow (131M), providing more financial flexibility.

Bottom Line

ONC scores higher overall (42/100 vs 21/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BeiGene, Ltd.

HEALTHCARE · BIOTECHNOLOGY · USA

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

RAPT Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company is headquartered in South San Francisco, California.

Visit Website →

Want to dig deeper into these stocks?